Debra Borchardt, Author at Green Market Report

Debra BorchardtDebra BorchardtMarch 23, 2018


Canadian-based CBD manufacturer Isodiol International Inc. (ISOLF) announced that it has signed a letter of intent to acquire 100% of KURE™ Corp.  The company, a leading specialty vape retailer headquartered in Charlotte, North Carolina, calls itself the ‘Starbucks’ of the vape industry. The amount was not disclosed, but KURE reported unaudited annual revenues for fiscal 2018 of $8.8 million. The deal is expected to close by the end of April 2018.

KURE has tried to differentiate itself from other vape shops by creating the KURE Vaporium & Lounge, a retail environment, and lounge catering to the vaping community. The company operates a total of twelve e-juice bars and lounges today, with plans for international expansion.

“We believe KURE to be the Starbucks (SBUX) of the specialty retail vape industry,” said  Craig Brewer, Chairman & CEO of KURE Corp. ” With over 200,000 customer transactions per year and growing, KURE’s knowledge base in the vape industry is exceptional. In joining the Isodiol family, we will now be able to provide our devout customers the very best CBD products on the market.”

KURE specializes in the retailing of vaporizers and e-cigarettes, e-juices, and related accessories. Its products are available online and throughout its store locations across the United States. KURE Vaporium & Lounge, KURE Society, Kuriousity, Kurators are all respective trademarks of KURE  Corp. Its e-Juices can be purchased pre-bottled or freshly mixed by its staff of “Kurators”, well-trained and experienced mixologists who can “blend” over 500,000 unique flavors from the KURE Juice On Tap bar.

“KURE’s executives are highly experienced business entrepreneurs that have done a tremendous job in building the KURE™ brand,” said Marcos Agramont, Chief Executive Officer of Isodiol.  “Not only does this further entrench our footprint in the vaping and e-cigarette industry, but through KURE retail stores, the Company will set up its own distribution channels for its family of brands, including ISO-Sport and Be Tru Wellness.”

“When we acquired Bradley’s Bioscience, we were excited about the prospects of providing safer alternatives to smoking, while at the same time being able to enter a market poised to be worth over $60 billion by 2025,” said Agramont.   “With this partnership, we will further entrench our footprint in this fast-growing industry, and we look forward to the global opportunities it presents for the Company.”

Isodiol stock was lately trading at 90 cents, down from its 52-week high of $1.69.

Debra BorchardtDebra BorchardtMarch 21, 2018


Canadian medical marijuana company Aphria Inc. (APHQF) announced that the shareholders of Nuuvera Inc. voted to approve a plan to allow Aphria to acquire all the shares not already owned. The original proposed plan was announced on January 29, 2018.

According to a statement, a total of 60,129,430 Nuuvera shares, representing approximately 67.15% of the outstanding Nuuvera shares, were represented in person or by proxy at the meeting. Of the votes cast with respect to the Arrangement, an aggregate of 60,073,288 Nuuvera shares were voted in favor of the Arrangement, representing approximately 99.90% of the votes cast on the resolution.  In addition, an aggregate of 47,193,288 Nuuvera shares, representing approximately 99.88% of the votes cast on the resolution excluding such shareholders as are required to be excluded pursuant to MI 61-101, were voted in favor of the arrangement.

Nuuvera is a Canadian cannabis company that is currently working with partners in Germany, Israel, and Italy , and is exploring opportunities in several other countries, to develop commercial production and global distribution of medical grade cannabis in legalized markets. The company also owns the subsidiaries, ARA – Avanti and Avalon Pharmaceutical Inc. Nuuvera holds a Dealer License (GMP) and is currently in the final stages of the Health Canada review process to become a Licensed Producer of medical marijuana under the ACMPR, and has recently received its “letter to build” approval.


Aphria also announced that it has signed an exclusive supply agreement with an Argentinan based pharmaceutical import and distribution company, which is licensed to import, sell and distribute medical products and derivatives in Argentina. The importer is currently securing an import license for cannabis in Argentina. Financial terms and the name of the importer were not released.

“We are excited to enter the Argentinian market through this initial supply agreement,” said Vic Neufeld, CEO of Aphria. “We see tremendous potential for medical cannabis in several emerging markets in South America, including Argentina. As the leading low-cost supplier of high-quality medical cannabis, Aphria will continue to expand its global leadership through strategic investments, partnerships and exclusive agreements such as this one.”

Debra BorchardtDebra BorchardtMarch 21, 2018


A new report suggests that the California cannabis market growth may be slowed due to heavy taxes and restrictive regulations. “California: The Golden Opportunity” written by Arcview Market Research in partnership with BDS Analytics writes that even the state’s revenue gains could be affected by the onerous tax and regulatory burdens that will drive consumers to the black market – exactly the opposite of what authorities wanted.

The report stated that the taxes and regulations amount to a 77% handicap versus the prices in the illicit market. California already had high sales taxes and now that is compounded by new cultivation and excise taxes. In addition to that, cannabis businesses are subject to the costs of navigating 40+ different types of state licenses. All of these costs ultimately trickle down to the consumer.

“While California cannabis companies are thrilled with the traffic increase they’ve seen since January 1 they can’t help but worry that regulations and taxes are going to handicap the legal market in the long term,” said Troy Dayton, CEO of the Arcview Group. “It’s clear that every additional penny of a price increase on legal cannabis products only serves to boost the attractiveness of purchasing from the illicit market which has flourished in the state for decades.”

To get an idea of how pervasive the black market is in California, the State Department of Food and Agriculture reported that cannabis cultivators (both legal & illegal) grew 13.5 million pounds of flower in 2016. However, residents only consumed 2.5 million and the rest was diverted to the black market. The bad players have little incentive to abide by the law because as part of the legalization process, punishment for breaking drugs laws have been lightened.

The report said that long-time illicit market customers were shocked when they saw the prices in legal dispensaries. Around 50% of California consumers surveyed in BDS Analytics’ “Public Attitudes and Actions Toward Legal Cannabis” reported buying cannabis from a friend, family member, or acquaintance. This market is big and very much ingrained in the state. Meaning there will be stiff competition between the legal and illegal businesses.

That competition isn’t helped when the legal operators are forking over higher taxes than in Colorado and Oregon with local municipalities adding their own taxes on top. A hypothetical $1,400 pound of cannabis effectively ends up costing $4,054 at retail and puts cannabis businesses at a serious disadvantage to the illicit players who have little overhead costs.

Ultimately the state could be cutting off its nose to spite its face with the extra regulatory and tax burdens. States have mostly legalized recreational marijuana so that they can reap the benefits of huge tax receipts. Cannabis sales in California are expected to hit $3 billion in 2018 larger than the states of Colorado, Oregon and Washington combined. The tax revenue is expected to exceed $649 million in 2018, so this is a significant source of income that the state will want to protect and grow.

While the numbers seem generous, they could be even bigger. The report notes that its forecast puts sales at $7.7 billion by 2021. “That sounds like a lot of growth, and it is, but the forecast is conservative compared to the post-adult-use legalization growth seen in other states. During the first three years (from 2017 through 2020), California’s market will increase at a compound annual growth rate (CAGR) of just under 29%—versus the 84% seen in Washington, 57% in Oregon, and 56% in Colorado during the first three years of adult-use in those states.” Still, the authors believe the politicians will be willing to make adjustments to ensure the success of the program.

“Rarely does a 20-year-old market undergo as radical a transformation in as short a time as California’s cannabis market did on January 1st of this year,” said Tom Adams, Editor-in-Chief at Arcview Market Research and Principal Analyst at BDS Analytics. “Suddenly, 29 million adults had access to the cornucopia of the modern cannabis store but were also suffering sticker shock from the state-imposed costs of going legal.”

On a positive note, the authors of the report believe that medical patients will be excited to see a new range of products available to them in the legal market. They also think that long-time black market consumers will find that the quality of the legal products is better and the options in the legal dispensaries more plentiful. Plus, there will be many consumers who did not want to engage in the illegal market, but now will be comfortable entering a legal dispensary.

In addition to the analysis of the illegal market, the report does a deep dive into all of the complicated regulations affecting the businesses, plus an exhaustive review of the various regions and counties.  It delves into the conflict of the inner state areas not wanting to be a part of the cannabis industry versus the coastal areas that seem to be all in.


Debra BorchardtDebra BorchardtMarch 20, 2018


Here are the cannabis news briefs for March 20, 2018:

 Arena Pharmaceuticals Inc.

Arena Pharmaceuticals (ARNA) reported positive results from a phase 2 trial of its treatment for ulcerative colitis. After the market closed on Monday the company released a statement saying that a higher dose of its experimental drug etrasimod succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study. The U.S.-based company said it now plans on moving the drug to late-stage trials. A lower dose did not have such strong results. The company is looking for a positive compound following the lower than expected sales of its weight-loss drug and is hoping this drug will make up for that disappointment.

The Supreme Cannabis Company, Inc.

Supreme Cannabis Company (FIRE.V) announced it has entered into a definitive agreement to complete a C$10,000,000 strategic equity investment in Medigrow. Upon completion of the investment, Supreme will own approximately 10% of Medigrow.

Namaste Technologies Inc.

Namaste (CSE:N) (NXTTF) announced that it has signed a Medical Cannabis Supply Agreement with Marigold Projects Jamaica Ltd. under its wholly owned subsidiary, Cannmart where Marigold will supply Cannmart with high-quality Jamaican produced medical cannabis, to be imported by Cannmart from Jamaica and offered in the Company’s online marketplace, subject to approval by Health Canada and the Cannabis Licencing Authority.

 Invictus MD Strategies Corp.

Invictus MD Strategies (TSXV: GENE) (OTC: IVITF) changed its share ticker from IMH to GENE on the Toronto Stock Exchange Venture Exchange. Invictus changed its TSX Venture symbol from IMH to GENE, effective March 20, 2018, to reflect the importance of the company’s new partnership with rock icon and branding genius Gene Simmons, anticipating that Simmons will play a vital role as the company marches into this historic year for Canada and cannabis.

The Hydropothecary Corporation

Hydropothecary (TSX-V: THCX) has reached an agreement with online commerce company Shopify to build its e-commerce platform for cannabis products. The bilingual website will serve Hydropothecary’s medical customers, provide information for discerning recreational consumers and support engagement with provincial and territorial cannabis retailers.

Friday Night Inc.

Friday Night Inc. (CSE: TGIF) (OTCQB: TGIFF) announced its inclusion in the CSE25 Index which is comprised of the 25 largest companies in the Canadian Securities Exchange Composite Index by market capitalization. The CSE25 Index is a subset of the CSE Composite Index.

Brayden Sutton, CEO of Friday Night, remarked, “We are very proud to be recognized as one of the 25 largest companies on the CSE by market capitalization. The inclusion of the CSE25 Index not only distinguishes our Company as a highly liquid issuer but gives validation to our business strategy and recognizes our impressive growth over the last 9 months of trading.”

Debra BorchardtDebra BorchardtMarch 19, 2018


Applied DNA Sciences (APDN) wants to use DNA tagging to track and verify cannabis strains. It wants to do for the cannabis industry what it did for the cotton industry – assure consumers that they are getting what they pay for. This Stony Brook, NY company has the ability to use DNA tagging to keep supply chains from being corrupted and make sure products are honest.

The Pima cotton story is the best way to explain this technology and why the company wants to apply the same process to the cannabis industry. Applied DNA Sciences began testing cotton products and realized consumers were spending extra money to purchase what they thought were premium cotton products called Pima. The makers of these Pima cotton sheets, towels and apparel believed that they were selling Pima products until it was proven that they weren’t. But whether it was the farmer or the factories in China that began blending non-Pima fibers into the finished product, the end result was that customers weren’t getting the Pima cotton they were paying for.

Applied DNA Sciences now tags most cotton following the harvest and then tests fibers, yarns, fabrics and even the finished product. Manufactures and consumers can now trust that whatever Pima cotton product they are buying, it is, in fact, a Pima cotton product.

That strain pride exists in the cannabis industry as well. Cannabis cultivators create and develop specific branded strains. Likewise, customers are very fond of popular strains like Blue Dream, Girl Scott Cookies or GG#4. The question is whether the cultivators are actually growing what they think they are growing and are the customers really getting the strain they think they are buying?

Canadian researchers from the University of British Columbia along with Sean Myles, a population geneticist at Dalhousie University conducted a strain study. They found only a moderate correlation between the marijuana reported by cultivators and the ancestry claimed. For example, a sample of Jamaican Lambs Bread, which is classified as cannabis sativa, was almost identical at a genetic level to a cannabis indica strain from Afghanistan. “Cannabis breeders and growers often indicate the percentage of Sativa or Indica in a cannabis strain, but they are not very accurate,” Page explained.

This could be avoided says Applied DNA Sciences. The company can apply a molecular tag to the plant which is unique to each cultivator. This is becoming increasingly important as farms invest thousands into their brands and they want to try to protect their strains as master growers move amongst different companies. This tag can be detected in plant material before and after drying. Their product is called CertainT.

“We knew we could spray the plant. We had done it with cotton, but we didn’t know what would happen after the processing of the plant,” said Gordon Hope, Director of Security Solutions. The company is now testing edible products to make sure the DNA tag can withstand the heating process during cooking.

A DNA tagging process could do that.With the CertainT tag, a manufacturer can be assured that the plant it buys from a cultivator is in fact what they believe they are buying. A customer can be certain that the strain they are purchasing is, in fact, that strain. The process can also be used to assist in regulatory compliance so that authorities can determine the origin of the product. Right now, the product on a shelf in a New York dispensary can be tracked by a seed-to-sale program but there is no way for the state to verify that the product was in fact grown in New York. A DNA tagging process could do that.

The tag can’t be compromised or copied. Even the U.S. Department of Defense relies on these tags to ensure the integrity of critical components such as lubricating oil or specific engine parts.

“They’ve got millions invested. They’re trying to protect their intellectual property, their trade secrets, their knowledge and their know-how,” said Hope. “Remember, most people can’t see the grow operations.” Hope also said that the medical marijuana companies he spoke to told him that their biggest problem is consistency. “Medical marijuana producers are very much concerned with consistency for their patients,” he said. “Large pharmaceutical companies don’t have this issue, but its critical for patients taking medical marijuana to know they are getting the exact same medicine for every dose.”

The company said it is sensitive to not adding a burden to the system. John Shearman Director of Marketing said, “We can be a nice overlay to provide that comfortable feeling and brand recognition.” They want to make it easy to run a test to verify a product’s origin. “A processor could be mixing in products that a brand isn’t able to verify and check,” he said.

In addition to helping processors and manufacturers, DNA Tagging can also help with regulatory authorities. The state should be able to check the product to make sure it is what it says it is. “If you want transparency in your system, you have no real way to assure that,” said Hope. “Everywhere along the supply chain, there is a chance for diversion. It could take 20 minutes to do the test. Even a dispensary could do the test on the product.”

Applied DNA Sciences currently has over 60 employees with 53 issued patents and 75 patent applications pending. The company has been testing its CertainT on cannabis in the state of Michigan where medical marijuana has been legal since 2008.

“The good news is you need very little DNA,” said Hope. “It’s a critical element missing from seed to sale chain.”

Debra BorchardtDebra BorchardtMarch 19, 2018


Canadian medical marijuana company Tilray has signed a binding letter of intent (LOI) to collaborate with generic pharmaceutical company Sandoz Canada Inc., an affiliate of Sandoz International GmbH, which is part of the Novartis Group (NVS).  The two companies are working together in order to accelerate innovation and increase the availability of high-quality cannabis products.

“This agreement is a major milestone on the long road to legitimizing medical cannabis as conventional medicine,” said Brendan Kennedy, Chief Executive Officer of Tilray. “Tilray is pleased to be what we believe is, the first federally licensed producer of medical cannabis to form a strategic alliance with a local affiliate of a global pharmaceutical company to improve the availability and quality of medical cannabis products for Canadian patients in need.”

The agreement builds on Tilray’s track record as a company that makes pharmaceutical grade medical cannabis. It was the first medical cannabis company to obtain current Good Manufacturing Practice (cGMP) certification in accordance with the EMA. The company supplies thousands of patients in ten countries.

With this collaboration, Tilray will be able to leverage the Sandoz salesforce to better educate pharmacists and physicians about medical marijuana. It will become the exclusive partner of Sandoz with respect to non-smokable/non-combustible medical marijuana products. The two companies will also develop new medical cannabis products that aren’t smokable.

They hope that in the future, if there are regulatory changes, Tilray will be able to capitalize on Sandoz’s supply chain with Canadian hospitals and pharmacies.

Tilray is a private company owned by Privateer Holdings.  Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; PEAR Therapeutics. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland. The Sandoz segment of the company provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services.


Debra BorchardtDebra BorchardtMarch 15, 2018


Here are today’s quick hits:

TerraTech Corp.

TerraTech (TRTC) rescheduled its earnings call scheduled for Thursday and postponed it to Friday. Sometimes these types of postponements are purely technical in nature, i.e. the accountants need to confirm numbers or language needs to be tweaked. However, it is usually not a positive sign when things aren’t finalized at this late moment. Hopefully, the delay wasn’t due to something substantial.


DELTA 9 CANNABIS (TSXV: NINE) has signed a Memorandum of Understanding to purchase up to 5,000 kilograms of cannabis from Alberta-based Sundial Growers Inc. The purchase is designed to increase Delta 9’s ability to meet the anticipated market demand following the full legalization of adult-use cannabis in Canada. The agreement commits Sundial to supply up to 5,000 kilograms of both dried cannabis and/or cannabis derivatives “to meet or exceed” Delta 9’s market demand in the period post-legalization. Delta 9 CEO John Arbuthnot says the agreement was reached as part of the company’s commitment to supply the Manitoba market.

CannaRoyalty Corp.

CannaRoyalty (CNNRF) announced that it has signed a binding term sheet to expand its business relationship with National Access Cannabis Corp. to carry CannaRoyalty products in NAC stores across Canada. According to a statement, NAC is in the process of applying for licenses in several Canadian jurisdictions and recently announced that it was one of four entities that have received conditional approval for a license to operate private retail cannabis stores across Manitoba. The agreement covers the purchase by NAC of certain CannaRoyalty products.

Marapharm Ventures Inc.

Marapharm Ventures (MRPHF) announced that its final plans for the company’s first cultivation facility in Desert Hot Springs, California are complete and ready for submission to the city. Basically saying that it was still on schedule to meet its construction goals.

Global Payout Inc.

Global Payout Inc. (GOHE) announced that its subsidiary MoneyTrac Technology had begun the soft launch of MTRAC, a full-service banking solution powered by software technology features that the company had acquired through its Joint Venture with GreenBox. MTRAC is an E-Wallet cash loading machine/kiosk that is supported by blockchain technology and will be leveraged by MTRAC in a system that will offer cannabis consumers and retailers an effective alternative to cash payment transactions.

Debra BorchardtDebra BorchardtMarch 14, 2018


Here are today’s quick hits for March 14, 2018:

Biopharmaceutical company GW Pharmaceuticals plc (GWPH announced that it received Notices of Allowance for five new Epidiolex® patent applications that will be listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) if the NDA for Epidiolex is approved. Once issued, these patents are set to expire in 2035. One or more patents may be eligible for additional patent term through patent term adjustment and/or regulatory exclusivities.

Canna-Hub, a California-based real estate development and property management Company for the cannabis industry, is accepting lease commitments at a new 16-acre cannabis community in the city of Mendota, California. The New York Times previously profiled Mendota – once known as the Cantaloupe Capital of the World – and its struggle with a high unemployment rate and lack of industry. Now, Sacramento-based Canna-Hub has secured a 16 acre site in Mendota for cannabis business operations.

Sipp Industries, Inc. (SIPC) announced that the recent run of its premier craft hemp beer, Major Hemp Brown Ale, has been well received by current and new customers. Major Hemp President Ted Jorgensen commented, “We have been extremely productive over the past thirty days and it’s a great testament to Major Hemp Brown Ale to see all the reorders and new customer interest.  Sales have been better than we expected.  The team at Colorado Craft Distributors has done a fantastic job fulfilling new orders and sample requests.  We expect the pace to accelerate over the next thirty to forty-five days with our combined sales and marketing efforts.”

Bespoke Extracts, Inc. (BSPK), producer of high quality, great tasting hemp-derived CBD extract products, today announced that it will debut its title sponsorship of the Hairy Kiwi Racing Team and professional racer Robertino Pietri at the 77th annual running of DAYTONA 200, America’s most historic motorcycle road race scheduled to take place this weekend at the iconic Daytona International Speedway in Florida.

Sublime Concentrates, an innovative cannabis manufacturing company, recently announced that it is changing its name to Sublime Canna. The new name better reflects the company’s expansion into other cannabis products, including sweet and savory edibles, as well as medicated dog treats.

Debra BorchardtDebra BorchardtMarch 14, 2018


San Diego-based Arena Pharmaceuticals, Inc. (ARNA) reported revenues of $15.4 million versus $69 million for the same time period last year. The company recorded a net loss of $13.7 million or $0.35 per share for the fourth quarter easily beating the estimate for a loss of $0.59 per share, but worse than last year’s net income of $38 million or $1.59 per share.

For the full-year, Arena delivered revenues of $21.3 million, a huge drop from 2016’s revenues of $92 million. The company recorded a net loss of $91.4 million or $2.77 per share;  a whopping increase over last year’s loss of $22 million or $0.93 per share. On December 31, 2017, Arena had cash and cash equivalents and investments totaling $271.3 million.

“We’ve made significant progress in 2017, achieving the clinical and corporate objectives we set forth as a new team,” said Amit D. Munshi, president, and CEO of Arena.  “Our focus remains on advancing our potentially best-in-class or best-in-disease pipeline and driving further value in the Company. We look forward to the etrasimod Phase 2 data readout this month and are enthusiastic about the Phase 3 clinical program for ralinepag, which we expect to begin in the second half of 2018.”

 The most advanced investigational clinical programs for Arena are ralinepag (APD811), which will be commencing a Phase 3 program for pulmonary arterial hypertension (PAH), and etrasimod (APD334), which is in Phase 2 for a broad range of immune and inflammatory conditions.  Arena is also evaluating APD371 in Phase 2 for the treatment of pain associated with Crohn’s disease. In addition, Arena has collaborations with the following pharmaceutical companies: Everest Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries), Axovant Sciences GmbH (nelotanserin – Phase 2), Boehringer Ingelheim International GmbH (undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai Inc. (BELVIQ® – marketed product).

Arena stock was up over 4% in pre-market trading to $41. It is nearing its 52-week high of $44.50 and the stock moves further away from its 52-week low of $11.30. Eight analysts cover the stock with five at a buy rating and three with a hold rating.

Debra BorchardtDebra BorchardtMarch 13, 2018


New York-based High Street Capital has changed its name to Acreage Holdings and has pivoted from passive cannabis investing to a company that actively owns and manages medical marijuana facilities. The company plans on pursuing an initial public offering.

It’s one of the few multi-state cannabis companies that many have never heard of. It was founded in 2014 by Kevin Murphy and was one of the first platforms to invest systematically in the cannabis space.

Over the past four years, Acreage Holdings has won state-awarded licenses, recruited operators and provided growth capital to local businesses across 11 different states. Murphy recognized the massive opportunity and scale offered by the creation of a cohesive multi-state platform and late last year the company voted to aggressively pursue a strategic roll-up of its portfolio assets.

“The traditional benefits of scale for any business are dramatically amplified in the nascent world of cannabis,” said Kevin Murphy, CEO. “The difference between ‘good’ and ‘excellent’ execution is unusually large and we plan to take advantage of that by creating a template for excellence and delivering it systematically.” Acreage has nearly completed execution of its plan to fully control and manage the operations of all its assets across the country.

The operations of Acreage Holdings include three of the fundamental components of the cannabis value chain: cultivation, processing, and retail dispensaries. “Our goal is to be vertically integrated in all of the states in which we operate,” added Mr. Murphy. “That way we can ensure that the highest quality product gets delivered in a timely, efficient and reliable way for thousands of patients and customers across the country.”

Within the 11 states that Acreage Holdings currently operates, cannabis is expected to represent $9 Billion of retail revenue by 2020. Acreage Holdings is keenly focused on expanding its footprint and continuing acquisitions, with aspirations to become the dominant national platform in the space.  The company recently attended the ICR Conference in January in a heavily attended presentation.

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

@GreenMarketRpt – 7 hours

RT : This is a super important dynamic: As long as you can shop around for labs, there will be some that are more “friendly…

@GreenMarketRpt – 7 hours

RT : Review your team approach and from the week so far. How can you make adjustments to boost the p…

Back to Top